Sun Pharma is looking for products complementing their Indian specialty portfolio
Sun Pharmaceutical Industries Limited
Sun Pharma is an international speciality pharma company. We have a significant presence in the US through our subsidiary Caraco. In the rest of world markets, we have a strong ground network of 400 committed field force in 30 countries, with a pipeline of over 2,600 products of which 1600 are registered and marketed. We have 2,500-person strong sales team in India distributing through 2,000 stockists, We are now at a stage of rapid growth across geographies spanning Russia and CIS countries, China and South east Asia, Africa and Latin America, where we are rapidly emerging as a branded generic company of choice.
In India, we are among the largest pharmaceutical companies and command a 3.6% market share (ORG IMS Stockist Audit, Aug 2009). In India, we market over 500 products through 18 speciality marketing divisions that are built around chronic therapy areas. Typically, every year we introduce 25-30 new products. All of these are developed in-house supported by strong bulk synthesis, formulation development, bioequivalence and regulatory teams. CMARC (A prescription audit agency) has ranked us as No.1 in key chronic therapy areas of Neuropsychiatry, Cardiology, Orthopedics and Ophthalmology. We rank among the top 5 companies for Diabetology, Respiratory, Pain, Cancer and Gynecology.
We look at partnering and collaborating as an important strategic approach that will complement our growth in India and international markets. Our constant need is to add to our speciality product portfolio for prescription leadership in India. We also seek to strengthen our presence, with a complete basket of speciality products, in Russia and CIS countries, China and South East Asia, Africa, Brazil and Mexico. We are currently interested in in-licensing products that are already marketed or are in late stage clinical development in our key therapy areas.
We seek products that leverage our core strengths and complement our existing product portfolio in the following therapy areas:
- CNS disorders
- Diabetes and Metabolic disorders
- Allergy, Asthma and Inflammation
We also have strategic interest in licensing biosimilar products and new products based on recombinant/humanized monoclonal antibody technology that find use in these therapy areas We seek to establish a long term, mutually rewarding relationship based on exclusive marketing rights business model for the above listed geographies, as well as co-marketing or strategic alliances for co-development including clinical trials of products for necessary regulatory approvals.